22.37
15.07%
+2.93
시간 외 거래:
22.33
-0.04
-0.18%
Guardant Health Inc 주식(GH)의 최신 뉴스
Compared to Estimates, Guardant Health (GH) Q1 Earnings: A Look at Key Metrics
Zacks Investment Research
Guardant Health (GH) Reports Q1 Loss, Tops Revenue Estimates
Zacks Investment Research
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research
Guardant (GH) Gears Up for Q1 Earnings: Here's What to Expect
Zacks Investment Research
Curious about Guardant Health (GH) Q1 Performance? Explore Wall Street Estimates for Key Metrics
Zacks Investment Research
Key Takeaways From Guardant Health Analyst Ratings
Benzinga
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Zacks Investment Research
Analyst Expectations For Guardant Health's Future
Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
Benzinga
Insiders Buying Advance Auto Parts And 2 Other Stocks
Benzinga
Cancer Test Focused Guardant Health Stock Falls On FDA AdCom Update For Colorectal Test
Benzinga
4 Analysts Have This To Say About Guardant Health
Benzinga
Guardant Health (GH) Reports Q4 Earnings: What Key Metrics Have to Say
Zacks Investment Research
Guardant Health (GH) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Wall Street Analysts Think Guardant Health (GH) Could Surge 109.89%: Read This Before Placing a Bet
Zacks Investment Research
NeoGenomics (NEO) Q4 Earnings and Revenues Beat Estimates
Zacks Investment Research
Guardant Health (GH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Down -12.91% in 4 Weeks, Here's Why Guardant Health (GH) Looks Ripe for a Turnaround
Zacks Investment Research
Guardant Health (GH) Loses -13.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks Investment Research
Decoding 4 Analyst Evaluations For Guardant Health
Benzinga
Bull of the Day: NeoGenomics (NEO)
Zacks Investment Research
4 Cathie Wood Stocks Wall Street Thinks Will Skyrocket 83% to 168% in 2024
The Motley Fool
Blood-Based Colorectal Cancer CRC Screening Market Likely to Benefit From FDA's Panel Surprise Advisory Possibility: Analyst
Benzinga
S&P 500, Nasdaq Set For Weaker Open As 'FOMO' Rally Cools: Analyst Says Only 'Black Swan Could Upset Santa's Sleigh' Now
Benzinga
What 7 Analyst Ratings Have To Say About Guardant Health
Benzinga
Jim Cramer: Buy This Financial Stock, 'It's Up Substantially From Where It Was In The Spring'
Benzinga
7 Analysts Have This to Say About Guardant Health
Benzinga
자본화:
|
볼륨(24시간):